Endogena Therapeutics

Eye
#AMD #Endogena Therapeutics #FDA #Geographic atrophy #Ophthalmology

FDA gives green light for AMD treatment trials

The US Food and Drug Administration (FDA) has granted clearance for Endogena's Investigational New Drug (IND) application for EA 2351, a potential treatment for geographic atrophy (GA). GA is an advanced form of age-related macular degeneration (AMD). The first-in-human study is set to commence in 2024. The company is currently… Read More

#News #Regulatory

Ophthalmologist looks at retinal scan
#Artificial intelligence (AI) #Endogena Therapeutics #Ophthalmology #Phase I trial #Phase II trial #Retinitis pigmentosa

Retinitis pigmentosa drug proved safe in Phase I/IIa study

Endogena Therapeutics has completed the dose-escalation stage of its Phase I/IIa study of EA-2353 in retinitis pigmentosa (RP) with no clinically relevant or dose-limiting adverse events. Given the positive safety and tolerability profile, the study will now enrol patients into the expansion cohort, using the highest… Read More

#News

#Endogena Therapeutics #FDA #Ophthalmology #Orphan drugs #Priority Review #Retinitis pigmentosa

FDA Fast Track Designation for retinitis pigmentosa treatment

The US Food and Drug Administration (FDA) has designated the investigation of Endogena Therapeutics’ EA-2353 for the treatment of retinitis pigmentosa (RP) as a Fast Track development programme.   Fast Track is a process designed to enable patients to benefit earlier from important new drugs for serious conditions. … Read More

#News